Compugen Ltd. (USA)  

(Public, NASDAQ:CGEN)   Watch this stock  
2.80
-0.15 (-5.08%)
Aug 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.80 - 2.95
52 week 2.80 - 7.57
Open 2.92
Vol / Avg. 155,205.00/124,157.00
Mkt cap 145.13M
P/E     -
Div/yield     -
EPS -0.67
Shares 51.13M
Beta 0.60
Inst. own 13%
Aug 3, 2017
Q2 2017 Compugen Ltd Earnings Release (Estimated)
Aug 2, 2017
Q2 2017 Compugen Ltd Earnings Call - Webcast
Jul 13, 2017
Compugen Ltd Annual Shareholders Meeting
Jun 21, 2017
Compugen Ltd at JMP Securities Life Science Conference
Jun 6, 2017
Compugen Ltd at Jefferies Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin - -4425.00%
Operating margin - -4576.26%
EBITD margin - -4367.84%
Return on average assets -61.45% -36.97%
Return on average equity -71.49% -41.07%
Employees 98 -
CDP Score - -

Address

Bldg D, 26, Ha-Rokmim
HOLON, 5885849
Israel
+972-3-7658585 (Phone)
+972-3-7658555 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

Officers and directors

Martin S. Gerstel Chairman of the Board
Age: 73
Bio & Compensation  - Reuters
Anat Cohen-Dayag Ph.D. President, Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
Ari Krashin Chief Financial Officer
Age: 42
Bio & Compensation  - Reuters
Zurit Levine Ph.D. Vice President - Research and Discovery
Age: 47
Bio & Compensation  - Reuters
John Hunter Vice President - Antibody Research & Development
Age: 52
Bio & Compensation  - Reuters
Dov Hershberg Director
Age: 75
Bio & Compensation  - Reuters
Michal Preminger Ph.D. Director
Bio & Compensation  - Reuters
Yair Aharonowitz Ph.D. Independent External Director
Age: 74
Bio & Compensation  - Reuters
Ruth Arnon Independent Director
Age: 81
Bio & Compensation  - Reuters
Arie Ovadia Independent External Director
Age: 68
Bio & Compensation  - Reuters